» Articles » PMID: 35224309

Lipoprotein-biomimetic Nanostructure Enables Tumor-targeted Penetration Delivery for Enhanced Photo-gene Therapy Towards Glioma

Overview
Journal Bioact Mater
Date 2022 Feb 28
PMID 35224309
Authors
Affiliations
Soon will be listed here.
Abstract

Glioma is one of the most malignant primary tumors affecting the brain. The efficacy of therapeutics for glioma is seriously compromised by the restriction of blood-brain barrier (BBB), interstitial tumor pressure of resistance to chemotherapy/radiation, and the inevitable damage to normal brain tissues. Inspired by the natural structure and properties of high-density lipoprotein (HDL), a tumor-penetrating lipoprotein was prepared by the fusion tLyP-1 to apolipoprotein A-I-mimicking peptides (D4F), together with indocyanine green (ICG) incorporation and lipophilic small interfering RNA targeted HIF-1α (siHIF) surface anchor for site-specific photo-gene therapy. tLyP-1 peptide is fused to HDL-surface to facilitate BBB permeability, tumor-homing capacity and -site accumulation of photosensitizer and siRNA. Upon NIR light irradiation, ICG not only served as real-time targeted imaging agent, but also provided toxic reactive oxygen species and local hyperthermia for glioma phototherapy. The HIF-1α siRNA in this nanoplatform downregulated the hypoxia-induced HIF-1α level in tumor microenvironment and enhanced the photodynamic therapy against glioma. These studies demonstrated that the nanoparticles could not only efficiently across BBB and carry the payloads to orthotopic glioma, but also modulate tumor microenvironment, thereby inhibiting tumor growth with biosafety. Overall, this study develops a new multifunctional drug delivery system for glioma theranostic, providing deeper insights into orthotopic brain tumor imaging and treatment.

Citing Articles

Utilization of nanotechnology to surmount the blood-brain barrier in disorders of the central nervous system.

Luo Q, Yang J, Yang M, Wang Y, Liu Y, Liu J Mater Today Bio. 2025; 31:101457.

PMID: 39896289 PMC: 11786670. DOI: 10.1016/j.mtbio.2025.101457.


Brain-targeting drug delivery systems: The state of the art in treatment of glioblastoma.

Sun B, Li R, Ji N, Liu H, Wang H, Chen C Mater Today Bio. 2025; 30:101443.

PMID: 39866779 PMC: 11759563. DOI: 10.1016/j.mtbio.2025.101443.


Recent advances in spatio-temporally controllable systems for management of glioma.

Zhang H, Zhu W, Pan W, Wan X, Li N, Tang B Asian J Pharm Sci. 2024; 19(5):100954.

PMID: 39483717 PMC: 11525460. DOI: 10.1016/j.ajps.2024.100954.


Advanced gene therapy system for the treatment of solid tumour: A review.

Ma Y, Liao J, Cheng H, Yang Q, Yang H Mater Today Bio. 2024; 27:101138.

PMID: 39027677 PMC: 11255123. DOI: 10.1016/j.mtbio.2024.101138.


Demystifying the potential of lipid-based nanocarriers in targeting brain malignancies.

Mesut B, Al-Mohaya M, Gholap A, Yesilkaya E, Das U, Akhtar M Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(12):9243-9279.

PMID: 38963550 DOI: 10.1007/s00210-024-03212-6.


References
1.
Liu C, Cao Y, Cheng Y, Wang D, Xu T, Su L . An open source and reduce expenditure ROS generation strategy for chemodynamic/photodynamic synergistic therapy. Nat Commun. 2020; 11(1):1735. PMC: 7142144. DOI: 10.1038/s41467-020-15591-4. View

2.
Zou Y, Sun X, Wang Y, Yan C, Liu Y, Li J . Single siRNA Nanocapsules for Effective siRNA Brain Delivery and Glioblastoma Treatment. Adv Mater. 2020; 32(24):e2000416. DOI: 10.1002/adma.202000416. View

3.
Xu X, Wu J, Liu Y, Saw P, Tao W, Yu M . Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy. ACS Nano. 2017; 11(3):2618-2627. PMC: 5626580. DOI: 10.1021/acsnano.6b07195. View

4.
Park D, Cho J, Kwon O, Yun C, Choy J . Biodegradable Inorganic Nanovector: Passive versus Active Tumor Targeting in siRNA Transportation. Angew Chem Int Ed Engl. 2016; 55(14):4582-6. DOI: 10.1002/anie.201510844. View

5.
Zhu Q, Ling X, Yang Y, Zhang J, Li Q, Niu X . Embryonic Stem Cells-Derived Exosomes Endowed with Targeting Properties as Chemotherapeutics Delivery Vehicles for Glioblastoma Therapy. Adv Sci (Weinh). 2019; 6(6):1801899. PMC: 6425428. DOI: 10.1002/advs.201801899. View